Cidan inhibits liver cancer cell growth by reducing COX‑2 and VEGF expression and cell cycle arrest Corrigendum in /etm/10/4/1609

Li,Nan; Zheng,Donghai; Xue,Jie; Guo,Weixing; Shi,Jie; Sun,Juxian; Lu,Chongde; Zheng,Weida; Wu,Mengchao; Cheng,Shuqun

doi:10.3892/etm.2015.2351

Cidan inhibits liver cancer cell growth by reducing COX‑2 and VEGF expression and cell cycle arrest

Corrigendum in /etm/10/4/1609

Authors:
- Nan Li
- Donghai Zheng
- Jie Xue
- Weixing Guo
- Jie Shi
- Juxian Sun
- Chongde Lu
- Weida Zheng
- Mengchao Wu
- Shuqun Cheng
View Affiliations

Affiliations: Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Beijing Oncology Hospital Of Weida TCM, Beijing 100023, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/etm.2015.2351
Pages: 1709-1718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cidan is a traditional Chinese medicine formula that has been used for >10 years as an antitumor drug. In the present study, the antitumor effect of cidan on hepatocellular carcinoma (HCC) and the underlying molecular mechanisms were investigated. A total of 372 patients with primary HCC, as confirmed by pathological examination in the Eastern Hepatobiliary Surgery Hospital and Beijing Oncology Hospital of Weida TCM, were prospectively enrolled in the study. In total, 92 patients were treated with cidan capsules for three months postoperatively, while 280 patients served as controls. The efficacy of cidan was analyzed by monitoring associated symptoms and liver function tests, including measuring the levels of α‑1‑fetoprotein, α‑L‑fucosidase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and γ‑glutamyl transferase. In addition, in vivo analysis was performed using mice Hepa1‑6 xenograft models, while in vitro studies were performed with SMMC‑7721 and CSQT‑1 cells; this included cidan‑dependent cell viability and migration assays, cell cycle analyses and the evaluation of cidan effects on cyclooxygenase‑2 (COX‑2) and vascular endothelial growth factor (VEGF) mRNA transcription rates using quantitative polymerase chain reaction. The postoperative two‑year overall survival (77 and 58% for the cidan and control groups, respectively; P<0.01) and disease‑free survival (36 and 24% for the cidan and control groups, respectively; P<0.01) rates were superior in the cidan‑treated group when compared with the control. In addition, the size and weight of the tumor xenografts in the C57BL/6 mice were significantly reduced in a time‑ and dose‑dependent manner following cidan treatment (P<0.01). Cidan significantly reduced the cell viability of SMMC‑7721 and CSQT‑1 cells after four and five days when compared with the control (P<0.01). Furthermore, COX‑2 and VEGF mRNA expression levels decreased following cidan treatment (P<0.01), and cidan treatment resulted in enhanced G1 and G2/M cell cycle arrest of CSQT‑1 cells. Therefore, cidan effectively inhibited cell proliferation, reduced cell viability and downregulated COX‑2 and VEGF expression levels in hepatoma cells.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Darvesh AS, Aggarwal BB and Bishayee A: Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 13:218–228. 2012. View Article : Google Scholar : PubMed/NCBI
3	Li W, Gao Z, Yang C, et al: The estimation of prevalence, incidence, and residual risk of transfusion-transmitted human hepatitis B infection from blood donated at the Anhui blood center, China, from 2009 to 2011. PloS One. 8:e734722013. View Article : Google Scholar : PubMed/NCBI
4	Su Y, Norris JL, Zang C, Peng Z and Wang N: Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 17:532–541. 2013.PubMed/NCBI
5	Chen WQ, Zheng RS and Zhang SW: Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 32:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
7	Cheng JH, Chang G and Wu WY: A controlled clinical study between hepatic arterial infusion with embolized curcuma aromatic oil and chemical drugs in treating primary liver cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 21:165–167. 2001.[(In Chinese)]. PubMed/NCBI
8	Wang WX, Li TX, Ma H, et al: Tumoral cytotoxic and antioxidative phenylpropanoid glycosides in Smilax riparia A. DC. J Ethnopharmacol. 149:527–532. 2013. View Article : Google Scholar : PubMed/NCBI
9	Liang QL, Dai CC, Jiang JH, Tang YP and Duan JA: A new cytotoxic casbane diterpene from Euphorbia pekinensis. Fitoterapia. 80:514–516. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fang R, Houghton PJ and Hylands PJ: Cytotoxic effects of compounds from Iris tectorum on human cancer cell lines. J Ethnopharmacol. 118:257–263. 2008. View Article : Google Scholar : PubMed/NCBI
11	Duan JA, Wang L, Qian S, Su S and Tang Y: A new cytotoxic prenylated dihydrobenzofuran derivative and other chemical constituents from the rhizomes of Atractylodes lancea DC. Arch Pharm Res. 31:965–969. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lin H, Liu J and Zhang Y: Developments in cancer prevention and treatment using traditional Chinese medicine. Front Med. 5:127–133. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dong HY, Shao JW, Wang T, Guo YH and Yan LY: Effects on the activities and mRNA expression of CYP3A in rat's liver by four kinds of extracts from anti-cancer traditional Chinese medicines. Zhong Yao Cai. 31:68–71. 2008.[(In Chinese)]. PubMed/NCBI
14	Wang B, Peng XX, Sun R, et al: Systematic review of β-elemene injection as adjunctive treatment for lung cancer. Chin J Integr Med. 18:813–823. 2012. View Article : Google Scholar : PubMed/NCBI
15	Dai ZJ, Tang W, Lu WF, et al: Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell Int. 13:272013. View Article : Google Scholar : PubMed/NCBI
16	Lu JJ, Dang YY, Huang M, Xu WS, Chen XP and Wang YT: Anti-cancer properties of terpenoids isolated from Rhizoma Curcumae - a review. J Ethnopharmacol. 143:406–411. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wang Q, Luan W, Goz V, Burakoff SJ and Hiotis SP: Non-invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice. Liver Int. 31:1200–1208. 2011. View Article : Google Scholar : PubMed/NCBI
18	Hu HS, Cheng SQ, Shi J, et al: Establishment and characterization of a human hepatocellular carcinoma cell line CSQT-1 derived from portal vein tumor thrombus. Di Er Jun Yi Da Xue Xue Bao. 30:1–4. 2009.
19	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
20	Bauer JS, Schreiner CL, Giancotti FG, Ruoslahti E and Juliano RL: Motility of fibronectin receptor-deficient cells on fibronectin and vitronectin: collaborative interactions among integrins. J Cell Biol. 116:477–487. 1992. View Article : Google Scholar : PubMed/NCBI
21	Pang R, Tse E and Poon RT: Molecular pathways in hepatocellular carcinoma. Cancer Lett. 240:157–169. 2006. View Article : Google Scholar : PubMed/NCBI
22	Wong CM and Ng IO: Molecular pathogenesis of hepatocellular carcinoma. Liver Int. 28:160–174. 2008. View Article : Google Scholar : PubMed/NCBI
23	Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 270:24995–25000. 1995. View Article : Google Scholar : PubMed/NCBI
24	Libby P: Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 65:S140–S146. 2007. View Article : Google Scholar : PubMed/NCBI
25	Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B and Anand P: Potential of spice-derived phytochemicals for cancer prevention. Planta Med. 74:1560–1569. 2008. View Article : Google Scholar : PubMed/NCBI
26	Lu JJ, Dang YY, Huang M, Xu WS, Chen XP and Wang YT: Anti-cancer properties of terpenoids isolated from Rhizoma Curcumae - a review. J Ethnopharmacol. 143:406–411. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xu WS, Dang YY, Guo JJ, et al: Furanodiene induces endoplasmic reticulum stress and presents antiproliferative activities in lung cancer cells. Evid Based Complement Alternat Med. 2012:4265212012. View Article : Google Scholar : PubMed/NCBI
28	Lee SJ and Langhans SA: Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis. BMC Cancer. 12:442012. View Article : Google Scholar : PubMed/NCBI
29	Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M and D'Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett. 224:53–65. 2005. View Article : Google Scholar : PubMed/NCBI
30	Tung YT, Chen HL, Lee CY, et al: Active component of Danshen (Salvia miltiorrhiza Bunge), tanshinone I, attenuates lung tumorigenesis via inhibitions of VEGF, cyclin A, and cyclin B expressions. Evid Based Complement Alternat Med. 2013:3192472013. View Article : Google Scholar : PubMed/NCBI
31	Nie YL, Liu KX, Mao XY, Li YL, Li J and Zhang MM: Effect of injection of Brucea javanica oil emulsion plus chemoradiotherapy for lung cancer: a review of clinical evidence. J Evid Based Med. 5:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li XY: Immunomodulating components from chinese medicines. Pharm Biol 38 (Suppl 1). 33–40. 2000. View Article : Google Scholar